5 Key Factors to look for in a Pharmaceutical Company July 3, 2020

5 Key Factors to look for in a Pharmaceutical Company

The pharmaceutical industry, part of the healthcare sector, deals with the development, manufacturing and distribution of pharmaceutical products. Some of the largest pharmaceutical companies worldwide include Pfizer, Merck & Co, Johnson & Johnson and AbbVie. According to the Global Use of Medicines report from the IQVIA Institute for Human Data Science, the global market for pharmaceuticals reached $1.2 trillion in 2018 and was expected to grow to $1.5 trillion by 2023. In 2018, U.S. alone spent $485 billion, a staggering 40% of total global spending.

With the global search for vaccines against COVID-19, pharmaceutical companies were thrown into the spotlight. Some companies are directly involved in the development of COVID-19 vaccines, such as Johnson and Johnson and GlaxoSmithKline, while others are indirectly riding along with the trend. If you are looking to invest in a pharmaceutical company, the following can serve as a simple guide on the 5 key factors you may consider looking out for.

1. Liquidity Ratios

In the pharmaceutical industry, it takes money to make money. Pharmaceutical companies, on average, spend 17% of revenue on research and development (R&D). Such huge spending is necessary as these companies constantly rely on the development of new drugs for their growth. Even after the successful development of a drug, huge marketing expenses will be spent on generating awareness. Marketing is mainly done by sending paid representatives to persuade healthcare professionals and direct-to-consumers sales. As a case study, in 2019, Eli Lilly spent 25.1% of total revenue on R&D and 27.8% of total revenue on marketing, selling and administrative expenses.

As such, cash is vital to sustain the business. Investors may look out for the quick ratio which measures a company’s short-term liquidity to cover its day-to-day operating expenses. It is calculated by taking the sum of current assets minus inventories and dividing by total current liabilities. For more conservative investors, they may look out for the cash ratio which takes the total reserves of cash and cash-equivalents and dividing by total current liabilities. A high quick ratio or cash ratio gives the company the leeway to increase its spending when the need arises, for example, pushing its marketing for newly developed drugs. Below is a table of comparison of the 5 largest pharmaceutical companies listed in the U.S.

Companies Total Cash Quick Ratio
Pfizer Inc 10.36 Billion 0.80
Novartis AG 4.76 billion 0.50
Merck & Co 7.44 billion 0.90
GlaxoSmithKline 4.86 billion 0.60
Johnson & Johnson 18.02 billion 1.00

Date last updated as of 12 June 2020

2. Debt Headroom/Debt Ratios

Other than depending on organic growth, large pharmaceutical companies may turn to acquisitions to boost their product portfolio and pipelines. Over the years, Eli Lilly has acquired a total of 23 various pharmaceutical companies. In 2007, the company acquired ICOS Corporation, gaining full control over the erectile dysfunction drug, Cialis. More recently in 2019, Pfizer acquired Array BioPharma Inc which gave it access to Array’s approved drugs for skin cancer and targeted cancer medicines.

Therefore, it is a common practice for companies to perform acquisitions to gain direct access to proven products. Other than having a huge cash pile to support these acquisitions, having sufficient debt headroom will ease some pressure off its short-term liquidity. The current low interest rate creates an ideal situation for these companies to have access to funds at cheap rates.

Investors can look out for the debt-to-equity ratio as a gauge of how the company is financing its operations through debt versus wholly-owned funds. The ratio is calculated by dividing a company’s total liabilities by its shareholder equity. Investors can also look out for the interest coverage ratio which measures the capacity of a company to pay their interest expenses on outstanding debt. The ratio is calculated by taking earnings before interest and taxes (EBIT) and dividing it by interest expense. Investors can take note that companies may choose to finance their acquisitions through cash and equity offering, and not necessarily through debt. However, with the debt headroom, it gives the company more financing options, especially if the cost of debt is significantly lower than the cost of equity. Below is a table of comparison of the 5 largest pharmaceutical companies listed in the U.S.

Companies Total Debt Debt-to-Equity Ratio
Pfizer Inc 52.29 Billion 80.03
Novartis AG 36.69 billion 71.98
Merck & Co 28.00 billion 106.46
GlaxoSmithKline 32.01 billion 159.26
Johnson & Johnson 27.58 billion 45.00

Date last updated as of 12 June 2020

3. Profitability of R&D spending

Despite huge R&D spending by pharmaceutical companies, R&D spending by itself does not necessarily guarantee results. For example, in 2016, Eli Lilly’s experimental drug for Alzheimer’s disease failed to produce positive results during its trial. This led to the company’s shares falling 13% in premarket trading on the announcement date. The bearish sentiments eventually spilled over onto other companies in the industry – Shares of Biogen Inc, which was developing a similar drug, tumbled 11% at that time.

Profitability of R&D spending is important because there is a huge opportunity cost involved when pharmaceutical companies allocate funds for R&D. The funds could potentially be spent on tangible assets or capital improvements, where results are clearly more visible. To have a gauge of profitability of R&D spending for a company, investors may look out for the return on research capital (RORC). It tells us how much gross profit is generated for every dollar of R&D spent. The ratio is calculated by taking the current year’s gross profit and dividing it by the previous year’s R&D expense. Investors may include this factor when doing peer comparison, to see which company is more efficient in terms of its R&D spending. Below is a table of comparison of the 5 largest pharmaceutical companies listed in the U.S.

Companies % of R&D Expenses to Revenue RORC
Pfizer Inc 17.12% 4.68
Novartis AG 18.35% 3.73
Merck & Co 21.11% 3.41
GlaxoSmithKline 13.50% 5.00 (GBP)
Johnson & Johnson 13.39% 4.82

Date last updated as of 12 June 2020

4. Pipelines of Products

Before new drugs hit the market, they have to be assessed by the FDA’s Centre for Drug Evaluation and Research (CDER) to ensure that it works as intended and the health benefits far outweigh the known risks. It involves a stringent process with a series of laboratory and human testing. Companies with only a few drugs in their pipelines may run the risk of hitting a brick wall if their drug applications are not approved. Having a full pipeline of drug spreads out risk and increases the chances of getting some approved. With that, investors may also look for pharmaceutical companies with a strong track record of passing FDA scrutiny and successfully taking drugs to the market.

Usually, most of the developed drugs will be protected under a patent. The patent protection will provide the company with a steady stream of cashflow until it eventually expires. Thereafter, the company may see competitors producing imitations. For example, in 2018, Teva Pharmaceuticals launched a copycat version of popular-selling erectile dysfunction drug, Cialis. This directly led to Eli Lilly’s sales for Cialis plunging 17%. Therefore, having a strong pipeline of products will ensure consistent growth of the company in the event that some patents expire near-term. Some companies may even come up with an improved version of the drug and protect it with a new patent, so as to ensure that they still have a competitive advantage of these products over their competitors.

5. Market Potential/Market Share

It is also important for investors to assess the market potential of the drugs owned by the pharmaceutical company. They can look at whether the condition treated by the drug affects a significant proportion of the population and if the product is essential. Pharmaceutical companies rely heavily on blockbuster drugs to bring in profits. These drugs are usually used to treat chronic medical problems, as opposed to acute or short-term conditions. Some examples are medications for diabetes, cholesterol, high blood pressure, and cancer. If a condition is long-lasting, consumers will have to depend on it for a prolonged period of time. This provides a form of recurring income for the pharmaceutical company.

Investors may also assess the market share that a company’s drug possesses. Having a high market share can be an indicator that the company’s drug has an edge over its competitors. It also shows how well the product is performing in relation to the industry as a whole. For example, Eli Lilly has been the market leader in several diabetes products. Its diabetes medication, Trulicity, has dominated 45% of market share in Q12020 and shows little sign of being dampened by any competition or pricing. Below is a table showing the top-selling drugs for the 5 largest pharmaceutical companies listed in the U.S.

Companies Top-Selling Drugs
Pfizer Inc Prevnar 13 | Lyrica | Ibrance
Novartis AG Gilenya | Cosentyx | Lucentis
Merck & Co Keytruda | Januvia | Gardasil
GlaxoSmithKline Triumeg | Advair | Tivicay
Johnson & Johnson Stelara | Remicade | Zytiga

Date last updated as of 12 June 2020

Generally, these are several key factors which you can consider when looking at a pharmaceutical company. There are definitely other factors that may come into play. For further analysis, one may consider conducting peer comparison and valuation measures to make a better-informed investing decision.


These commentaries are intended for general circulation. It does not have regard to the specific investment objectives, financial situation and particular needs of any person who may receive this document. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. Investors may wish to seek advice from a financial adviser before investing. In the event that investors choose not to seek advice from a financial adviser, they should consider whether the investment is suitable for them.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

About the author

Yeap Jun Rong
Investment Specialist
Phillip Investor Centre

Mr Yeap Jun Rong joined Phillip Securities since 2017, and currently manages a portfolio of over 10,000 trading accounts as an Investment Specialist. Apart from his dealing role, Jun Rong also frequently conducts seminars to empower his clients with financial knowledge in the field of both fundamental analysis and technical analysis.

He also regularly features in different media platforms such as Channel 8's Morning Express show and provides market commentary for various newspaper like LianHeZaoBao (联合早报) and Business Times.

Jun Rong graduated from National University of Singapore (NUS) in 2017 and holds a Bachelor’s Degree, majoring in Economics.

No Related Market Journal.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com